Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7903146 | 0.83 | TP53 (0.35) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL1764669 | 0.82 | TSHR (0.38) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL7098338 | 0.78 | TP53 (0.39) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL28063692 | 0.77 | SMN1; SMN2 (0.50) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL7855792 | 0.76 | TP53 (0.36) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL6157607 | 0.70 | TP53 (0.30) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL1004018 | 0.68 | CYP3A4 (0.59) | CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL28035980 | 0.67 | CYP3A4 (0.47) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL31465325 | 0.66 | CYP3A4 (0.43) | — | |
| SCHEMBL1006177 | 0.66 | CYP3A4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9358319-B2 | Cement products and methods of making and using the same | PIONEER SURGICAL TECHNOLOGY, INC. (US) | 2016-06-07 | — | — | US | claimed |
| US-20140357754-A1 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2014-12-04 | — | — | US | claimed |
| WO-2026101055-A1 | BATTERY ASSEMBLY | 주식회사 엘지에너지솔루션 | 2026-05-15 | — | — | WO | disclosed |
| US-20250368773-A1 | EPOXY RESIN, PRODUCTION METHOD FOR SAME, CURABLE RESIN COMPOSITION, AND CURED PRODUCT | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4650350-A1 | POLYCRYSTALLINE FORM OF BIPHENOL DIGLYCIDYL ETHER, AND RESIN COMPOSITION CONTAINING SAID POLYCRYSTALLINE FORM AND CURED PRODUCT THEREOF | Mitsubishi Chemical Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-12473471-B2 | Laminate, production method therefor, and automotive exterior material | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-11-18 | — | — | US | disclosed |
| US-12466936-B2 | Resin composition for semiconductor package, resin coated copper, and circuit board comprising same | LG INNOTEK CO., LTD. (KR) | 2025-11-11 | — | — | US | disclosed |
| US-20250340524-A1 | POLYCRYSTALLINE FORM OF BIPHENOL DIGLYCIDYL ETHER, AND RESIN COMPOSITION CONTAINING SAID POLYCRYSTALLINE FORM AND CURED PRODUCT THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-11-06 | — | — | US | disclosed |
| US-20250333565-A1 | CHEMICAL-RESISTANT PROTECTIVE FILM | NISSAN CHEMICAL CORPORATION (JP) | 2025-10-30 | — | — | US | disclosed |
| EP-4640733-A1 | EPOXY RESIN, PRODUCTION METHOD FOR SAME, CURABLE RESIN COMPOSITION, AND CURED PRODUCT | Mitsubishi Chemical Corporation (JP) | 2025-10-29 | — | — | EP | disclosed |
| EP-4516738-A1 | ZEOLITE, METHOD FOR PRODUCING ZEOLITE, COMPOSITION, LIQUID SEALING AGENT, RESIN COMPOSITE MATERIAL, SEALING MATERIAL, METHOD FOR PRODUCING SEALING MATERIAL, AND ELECTRONIC DEVICE | Mitsubishi Chemical Corporation (JP) | 2025-03-05 | — | — | EP | disclosed |
| EP-0526575-A1 | EPOXY RESIN SYSTEMS MODIFIED WITH LOW VISCOSITY STATISTICAL MONOFUNCTIONAL REACTIVE POLYMERS | THE B.F. GOODRICH COMPANY (US) | 1993-02-10 | — | — | EP | disclosed |
| US-5157077-A | Carboxyl, amine or epoxy-terminated reactive polymers | THE B. F. GOODRICH COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| US-5140068-A | Toughness, adhesion, elongation | THE B. F. GOODRICH COMPANY (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1991017213-A1 | EPOXY RESIN SYSTEMS MODIFIED WITH LOW VISCOSITY STATISTICAL MONOFUNCTIONAL REACTIVE POLYMERS | THE B.F. GOODRICH COMPANY (US) | 1991-11-14 | — | — | WO | disclosed |
| US-4332733-A | CATALYTIC ISOMERIZATION OF DIELS-ALDER MALEIC ANHYDRIDE PRODUCTS | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1982-06-01 | — | — | US | disclosed |
| US-4195138-A | CONTROLLING WATER HARDNESS BY REMOVING MULTIVALENT IONS | THE DOW CHEMICAL COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4189539-A | ION EXCHANGE RESIN | THE DOW CHEMICAL COMPANY (US) | 1980-02-19 | — | — | US | disclosed |
| US-4186086-A | CURED REACTION PRODUCT OF POLYAMINE AND POLYEPOXIDE | THE DOW CHEMICAL COMPANY (US) | 1980-01-29 | — | — | US | disclosed |
| US-3947395-A | Epoxy surface coating compositions | HITACHI, LTD. (JA) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340524-A1 | POLYCRYSTALLINE FORM OF BIPHENOL DIGLYCIDYL ETHER, AND RESIN COMPOSITION CONTAINING SAID POLYCRYSTALLINE FORM AND CURED PRODUCT THEREOF | RPP30, RER1, C9 | TP53 3306/4885CYP2C9 2005/4885CYP2C19 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.